Epstein-Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV.

"data availability statement sequence reads for with caebv and pid have been deposited in the european nucleotide archive (ena) under bioproject id prjeb41945. primary and secondary immunodeficiency was excluded and a diagnosis of caebv was considered (data s1 ).; data s1 . data availability statement sequence reads for with caebv and pid have been deposited in the european nucleotide archive (ena) under bioproject id prjeb41945"

"samples were sequenced and analysed using a standard pipeline and in-house r scripts ( supplementary methods ; figure s1 )."

"Conflict of interest The authors declare no conflict of interest."

"We thank Prof. Richard Goldstein [Division of Infection and Immunity, University College London (UCL)] and Dr Daniel P. Depledge (NYU Department of Medicine) for insightful comments and discussion. We acknowledge the support of the UK Medical Research Council (MRC)/National Institute for Health Research (NIHR) funded Pathogen Genomics Unit. Cristina Venturini was supported by the Wellcome Trust Collaborative Award (204870/Z/16/Z); Sofia Morfopoulou by a W.T. Henry Wellcome fellowship (206478/Z/17/Z). Paul J. Farrell was supported by MRC grant MR/S022597/1 and by NIHR Imperial Biomedical Research Centre (BRC). Judith Breueris supported by the NIHR UCL/UCLH BRC. This work was supported by the intramural research program of the National Institute of Allergy and Infectious Diseases."